Merck, Moderna claim encouraging melanoma vaccine trial results
US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.
The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer patients when used with Merck’s Keytruda treatment, the companies said in a statement.
Unlike conventional vaccines, so-called therapeutic vaccines like intismeran treat rather...
Merck, Moderna melanoma vaccine succeeds
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial IOL —
- Merck, Moderna Melanoma Vaccine Study Succeeds Bloomberg —
- Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times —
- Merck, Moderna Stocks Soar After Melanoma Trial Success 📹 Bloomberg — · 2min
- Moderna Cancer Trial Success Is a Shot in the Arm for Trump Newsweek —